Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2026)

Agios Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• Quarterly Operating Leases fell 68.0% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (down 68.0% YoY) and the FY2025 annual result came in at $21.8 million, down 45.74% from the prior year.
• Operating Leases was $16.9 million for Q1 2026 at Agios Pharmaceuticals, down from $21.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.8 million in Q3 2022 and bottomed at $16.9 million in Q1 2026.
• A 5-year average of $57.2 million and a median of $60.8 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases gained 0.0% — and 2026, when it sank 68.0%.
• Agios Pharmaceuticals' Operating Leases stood at $72.0 million in 2022, then declined by 20.85% to $57.0 million in 2023, then slipped by 29.45% to $40.2 million in 2024, then slumped by 45.74% to $21.8 million in 2025, then retreated by 22.35% to $16.9 million in 2026.
• Business Quant data shows AGIO's Operating Leases at $16.9 million in Q1 2026, $21.8 million in Q4 2025, and $26.5 million in Q3 2025.